• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Solifenacin Teva
    / Teva

    Active Ingredient
    Solifenacin Succinate 5 mg, 10 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 X 5 mg

    partial basket chart 49809 9728


    30 X 10 mg

    partial basket chart 49804 9727


    Adults:  including the elderly 5 mg once daily. If needed, the dose may be increased to 10 mg once daily.
    Children: Not recommended for children under 18 years.
    Renal impairment: Mild to moderate: No dose adjustment is necessary Severe: not more than 5 mg once daily.
    Hepatic impairment:  Mild: No dose adjustment is necessary, Moderate: not more than 5 mg once daily.
    Concomitant Use with Potent inhibitors of cytochrome P450 3A4: The maximum dose: 5 mg when treated simultaneously with ketoconazole or other potent CYP3A4-inhibitors.


    Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.



    Urinary retention, severe gastro-intestinal condition (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma and in patients at risk for these conditions.
    *  Patients hypersensitive to the active substance or to any of the excipients.
    *  Patients undergoing haemodialysis.
    *  Patients with severe hepatic impairment.
    *  Patients with severe renal impairment or moderate hepatic impairment and who are on treatment with a potent CYP3A4 inhibitor, e.g. ketoconazole.

    Special Precautions

    Refer to the manufacturer for additional information.

    Side Effects

    Refer to the manufacturer for additional information.

    Teva Pharmaceutical Industries Ltd, Israel